Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146179 | 0.83 | KDM4E (0.35) | PIK3CDKDM4E | |
| SCHEMBL897720 | 0.79 | KDM4E (0.36) | PIK3CDKDM4E | |
| SCHEMBL13158266 | 0.79 | KDM4E (0.34) | PIK3CDKDM4E | |
| SCHEMBL22529036 | 0.78 | KDM4E (0.35) | PIK3CDKDM4EMMP12MMP13 | |
| SCHEMBL19342028 | 0.77 | KDM4E (0.33) | PIK3CDKDM4E | |
| SCHEMBL21572217 | 0.75 | KDM4E (0.33) | PIK3CDKDM4E | |
| SCHEMBL3202818 | 0.74 | KDM4E (0.40) | PIK3CDKDM4E | |
| SCHEMBL13376432 | 0.74 | PIK3CD (0.38) | PIK3CDKDM4EMMP12MMP13 | |
| SCHEMBL4952545 | 0.72 | PDE3B (0.40) | PIK3CDKDM4E | |
| SCHEMBL13834914 | 0.72 | CA1 (0.34) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591334-B2 | Substituted pyrrolizines for the treatment of hepatitis B | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20200354366-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
| EP-3312172-B1 | AMINOPYRAZOLE DERIVATIVES USEFUL AS SRC KINASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-10479780-B2 | Aminopyrazole derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-11-19 | — | — | US | disclosed |
| WO-2016204261-A1 | AMINOPYRAZOLE DERIVATIVES | 中外製薬株式会社 | 2016-12-22 | — | — | WO | disclosed |
| EP-1131321-B1 | INDOLE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR LIGANDS | LILLY CO ELI (GB) | 2003-09-10 | — | — | EP | disclosed |
| EP-1235795-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDES | ELI LILLY AND COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6329366-B1 | HETEROCYCLIC, PIPERIDINE, INDOLE DERIVITIVES FOR TREATMENT OF NERVOUS SYSTEM DISORDERS AND SEROTONIN ANTAGONIST | ELI LILLY AND COMPANY LIMITED (GB) | 2001-12-11 | — | — | US | disclosed |
| EP-1131321-A2 | INDOLE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY LIMITED (GB) | 2001-09-12 | — | — | EP | disclosed |
| WO-2001036383-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDES | ELI LILLY AND COMPANY (US) | 2001-05-25 | — | — | WO | disclosed |
| WO-2000031074-A2 | INDOLE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY LIMITED (GB) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479780-B2 | Aminopyrazole derivatives | SRC, GRK2, GRK3 | PIK3CD 1023/4885KDM4E 1788/4885MMP12 4268/4885 |
| US-11591334-B2 | Substituted pyrrolizines for the treatment of hepatitis B | SLC10A1, NUP188, NR1H4 | PIK3CD 4127/4885KDM4E 4089/4885MMP12 3144/4885 |
| US-20200354366-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | SLC10A1, NR1H4, NUP188 | PIK3CD 4403/4885KDM4E 3421/4885MMP12 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.